Formulation Development

We believe that topical JAK inhibitor therapy for alopecia areata requires the drug to be delivered to the site of the inflammation, deep in the skin at the base (bulb) of the hair follicle. ARQ-255 is an alternative topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata.  Arcutis currently has formulation and preclinical efforts underway for ARQ-255, which if successful, will allow ARQ-255 to enter the clinic as potentially the only topical treatment for alopecia areata.